The artificial intelligence maker OpenAI may face a costly and inconvenient reckoning with its nonprofit origins even as its valuation recently exploded to $157 billion.
This week, a phase 3 clinical trial showed aztreonam-avibactam might be treatment option for patients facing multidrug-resistant infections. Meanwhile, research shows that penicillin allergies in ...